鄰近類別 圖書 [1/1] 會議論文/會議摘要 [115/179] 類別統計 近3年內發表的文件:59(17.82%) 含全文筆數:328(99.09%) 文件下載次數統計 下載大於0次:328(100.00%) 下載大於100次:313(95.43%) 檔案下載總次數:139123(77.75%) 最後更新時間: 2024-12-11 15:38 上傳排行 資料載入中..... 下載排行 資料載入中..... 最近上傳 Cooperative participation of CagA a... Pan-Asian adapted ESMO clinical pra... Nivolumab plus chemotherapy in pati... Survival of advanced/recurrent gast... Topiramate suppresses peri-infarct ... A phase 1 study of biweekly nab-pac... Plain language summary of the FOENI... Outcomes of post-immunotherapy dura... Durvalumab or placebo plus gemcitab... Impact of previous S-1 treatment on...

跳至: (選擇年份) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (選擇月份) January February March April May June July August September October November December 或輸入年份:

由新到舊排序 由最舊的開始

顯示項目151-175 / 331. (共14頁) << < 2 3 4 5 6 7 8 9 10 11 > >> 每頁顯示[10|25|50]項目

日期	題名	關聯
2017-09	KLF10 loss in the pancreas provokes activation of SDF-1 and induces distant metastases of pancreatic ductal adenocarcinoma in the KrasG12D p53flox/flox model	Oncogene. 2017 Sep;36(39):5532-5543.
2017-09	A phase II study of Arginine Deiminase (ADI-PEG20) in relapsed/refractory or poor-risk acute myeloid leukemia patients	Scientific Reports. 2017 Sep;7:Article number 11253.
2017-08	Overexpressed fatty acid synthase in gastrointestinal stromal tumors: Targeting a progression-associated metabolic driver enhances the antitumor effect of imatinib	Clinical Cancer Research. 2017 Aug;23(16):4908-4918.
2017-08	A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo	Cancer Chemotherapy and Pharmacology. 2017 Aug;80(2):307-315.
2017-07	A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17	Oncotarget. 2017 Jul;8(27):44121-44130.
2017-05	Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: A Q-TWiST analysis	British Journal of Cancer. 2017 May;116(10):1247-1253.
2017-05	A phase I dose escalation study of SCBO1A, a micro tubular inhibitor with vascular disrupting activity, in patients with advanced solid tumors refractory to standard therapy	Journal of Clinical Oncology. 2017 May;35(Suppl. 15):Meeting Abstract 2531.
2017-02	Nanoliposomal irinotecan in the clinical practice guideline for metastatic pancreatic cancer: Applicability to clinical situations	Journal of Clinical Oncology. 2017 Feb;35(6):689-690.
2017-02	The B-cell-activating factor signalling pathway is associated with Helicobacter pylori independence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21)	Journal of Pathology. 2017 Feb;241(3):420-433.
2017-02	Argininosuccinate lyase interacts with cyclin A2 in cytoplasm and modulates growth of liver tumor cells	Oncology Reports. 2017 Feb;37(2):969-978.
2017-01	Expressions of the CagA protein and CagA-signaling molecules predict H. pylori-dependence of early-stage gastric DLBCL	Blood. 2017 Jan;129(2):188-198.
2016-12	The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan	Asia-Pacific Journal of Clinical Oncology. 2016 Dec;12(4):396-402.
2016-11-21	A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors	BMC Cancer. 2016 Nov 21;16:Article number 907.
2016-10	Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor	Cancer Research and Treatment. 2016 Oct;48(4):1155-1166.
2016-10	BPR1J373, an oral multiple tyrosine kinase inhibitor, targets c-KIT for the treatment of c-KIT driven myeloid leukemia	Molecular Cancer Therapeutics. 2016 Oct;15(10):2323-2333.
2016-09	The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer	Oncotarget. 2016 Sep;7(38):61136-61151.
2016-08	Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma	Journal of Hepatology. 2016 Aug;65(2):296-304.
2016-07	Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer	Expert Opinion on Pharmacotherapy. 2016 Jul;17(10):1413-1420.
2016-05-14	Nanoliposomal irinotecan in metastatic pancreatic cancer - Authors' reply	Lancet. 2016 May 14-20;387(10032):1997.
2016-05-03	Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer	Scientific Reports. 2016 May 3;6:Article number 25369.
2016-05	Overexpression of regulator of G protein signaling 11 promotes cell migration and associates with advanced stages and aggressiveness of lung adenocarcinoma	Oncotarget. 2016 May;7(21):31122-31136.
2016-05	Efficacy of frontline antibiotics therapy in the treatment of Helicobacter pylori-negative gastric low-grade mucosa-associated lymphoid tissue lymphoma	Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number e19024.
2016-03	miR-520h is crucial for DAPK2 regulation and breast cancer progression	Oncogene. 2016 Mar 3;35(9):1134-1142.
2016-03	Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer	Oncogene. 2016 May;35(12):1517-1528.
2016-02	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial	Lancet. 2016 Feb;387(10018):545-557.

顯示項目151-175 / 331. (共14頁) << < 2 3 4 5 6 7 8 9 10 11 > >> 每頁顯示[10|25|50]項目